US3683023A - Amino-guanidine derivatives - Google Patents
Amino-guanidine derivatives Download PDFInfo
- Publication number
- US3683023A US3683023A US828366A US3683023DA US3683023A US 3683023 A US3683023 A US 3683023A US 828366 A US828366 A US 828366A US 3683023D A US3683023D A US 3683023DA US 3683023 A US3683023 A US 3683023A
- Authority
- US
- United States
- Prior art keywords
- guanidine
- percent
- blood pressure
- theory
- yield
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/52—Nitrogen atoms not forming part of a nitro radical with hetero atoms directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
Definitions
- R and R are each hydrogen or lower alkyl
- alkylene containing two to three carbon atoms and when joined together form alkylene containing two to three carbon atoms, and X is phenyl substituted by at least one halogen atom, and the salts thereof with pharmaceutically acceptable acids.
- R and R which may be the same or different, are each hydrogen atoms or lower alkyl and when R, and R are joined together form alkylene containing two or three carbon atoms and X is phenyl substituted by one or more halogen atoms; and the salts thereof with physiologically compatible acids.
- the new compounds (I) are valuable pharmaceuticals and canbe successfully used for the regulation of. the blood pressure and are particularly suitable for use in the treatment of hypertonias.
- the new guanidine derivatives (I) can be prepared, for example, by the reaction of a hydrazine having the formula:
- R has the same significance as given above, or if R, and R are hydrogen'or lower alkyl, by the reaction of a compound having the-formula:
- R is hydrogen or lower alkyl and X and have the same meanings as given above, with a compound having the formula:
- Tetrahydrofuran has proved to be particularly useful as a polar, inert solvent.
- reaction products is carried out by converting the same by the conventional methods into their physiologically compatible salts, for example, by neutralization with an appropriate organic or inorganic acid.
- physiologically compatible salts there may be mentioned, in particular, the hydrochlorides, hydrobromides, sulfates, phosphates, tartrates, citrates and oxalates of the free bases (I).
- EXAMPLE 2 (3-chloroanilino)-guanidine 7.1 g m-chlorophenyl-hydrazine (0.05 mol) were first heated, while passing nitrogen through the mixture, with 7.7 g S-methyl-isothiuronium bromide for 30 minutes at C and then for 30 minutes at C.
- the compounds of the invention constitute potent antihypertensive agents.
- the compounds have proved particularly effective in the treatment of patients with severe or sustained elevation of blood pressure, particularly diastolic pressure.
- the compounds are suitable for use in almost all forms of fixed and progressive hypertensive disease, including that in which blood pressure is moderately elevated.
- the compounds have also proved efiective in renal hypertension, including hypertension secondary to pyelonephritis, glomerulonephritis and renal amylordosis.
- the compounds can be administered orally, as pills, tablets, capsules, powders and the like.
- the preferred form of oral administration is as a tablet containing 10 to 25 mg of active compound.
- the compounds can also be administered parenterally.
- injection solutions containing 10 mg/ml of injection solution are preferred.
- the dosage schedule is entirely dependent on the condition of the patient, his response to the treatment and whether or not he is ambulatory or hospitalized.
- the treatment should be begun with small doses (10 mg) and increased gradually depending upon the patients response.
- the dosage can be increased at 5 to 7 day intervals until an average daily dose of 25 to 50 mg is reached. Only one dose a day is usually required.
- Rats each weighing 250-300 g were used as test animals. Experimental hypertension was induced in these animals by administering to them over a 4 week period ll-desoxycorticosterone-acetate (5 mg-twice weekly subcutaneously and by supplying them with a feed containing 10 percent sodium chloride. After this period, during which experimental high blood pressure had been achieved, an arterial tonometer catheter was surgically implanted into the carotid artery of each of the animals. Blood pressure measurements were carried out using an electromechanical pressure converter (Statham element) and a direct writing system (Schwarzer system) for recording the same. After the control values had been determined, the animals were given the test substance dissolved in physiological saline, the test drugs being supplied by an esophageal catheter.
- guanethidine (Ismelin Ciba) [2-(octahydro-l-azocinyl)-ethyl]-guanidine sulfate was used.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Amino-guanidine derivatives constituting blood pressure regulating agents and being characterized by their ability to decrease blood pressure having the formula: WHEREIN R1 and R2 are each hydrogen or lower alkyl, and when joined together form alkylene containing two to three carbon atoms, and X is phenyl substituted by at least one halogen atom, and the salts thereof with pharmaceutically acceptable acids.
Description
United States Patent Winter etal.
[54] AMINO-GUANIDINE DERIVATIVES [72] Inventors: Werner Filed:
May 27, 1969 Appl. No.: 828,366
Foreign Application Priority Data July 9, 1968 Germany ..P I7 68 867.4
U.S. Cl......260/564 F, 260/256.4 R, 260/308 R,
260/309.6, 260/310 R, 260/50l.l4, 260/564.
Int. Cl.....' ..C07c 129/08 Field of Search ..260/564 F Aug. 8, 1972 [56] References Cited UNITED STATES PATENTS 3,383,409 I 5/1968 Bream et al. ..260/50l.l4
OTHER PUBLICATIONS Chemical Abstracts, Vol. 67, 32382(a) I967).
Primary Examiner-Leon Zitver Assistant Examiner-Gerald A. Schwartz Attorney-Burgess, Dinklage & Sprung ABSTRACT Amino-guanidine derivatives constituting blood pressure regulating agents and being characterized by their ability to decrease blood pressure having the formula:
I wherein R and R are each hydrogen or lower alkyl,
and when joined together form alkylene containing two to three carbon atoms, and X is phenyl substituted by at least one halogen atom, and the salts thereof with pharmaceutically acceptable acids.
5 Claims, No Drawings wherein R and R which may be the same or different, are each hydrogen atoms or lower alkyl and when R, and R are joined together form alkylene containing two or three carbon atoms and X is phenyl substituted by one or more halogen atoms; and the salts thereof with physiologically compatible acids.
In accordance with the invention it has now been found that the new compounds (I) are valuable pharmaceuticals and canbe successfully used for the regulation of. the blood pressure and are particularly suitable for use in the treatment of hypertonias.
The new guanidine derivatives (I) can be prepared, for example, by the reaction of a hydrazine having the formula:
X NH NI-I (II) wherein X has the same significance as given above, either with an isourea derivative having the formula:
Nit
NH-Rz (III) wherein Z is a reactive group which can easily be split off and R, and R have the same significances as given above, or, if R is hydrogen, with a cyanamide having the formula:
R,-NI-l-CN iv wherein R, has the same significance as given above, or if R, and R are hydrogen'or lower alkyl, by the reaction of a compound having the-formula:
wherein R is hydrogen or lower alkyl and X and have the same meanings as given above, with a compound having the formula:
reacted with the compounds (VI) either by heating in a polar, inert solvent or, without the use of a solvent, simply by melting the components together, preferably in an atmosphere of nitrogen or in a vacuum.
Tetrahydrofuran has proved to be particularly useful as a polar, inert solvent.
The isolation of the reaction products is carried out by converting the same by the conventional methods into their physiologically compatible salts, for example, by neutralization with an appropriate organic or inorganic acid.
As examples of physiologically compatible salts, there may be mentioned, in particular, the hydrochlorides, hydrobromides, sulfates, phosphates, tartrates, citrates and oxalates of the free bases (I).
The following examples are given for the purpose of illustrating the present invention; the same are however, not to be construed as in any way limiting the scope thereof.
EXAMPLEI (3-chloroanilino)-guanidine 28.4 g (0.2 mol) m-chlorophenyl-hydrazine were heated under reflux with 29.4 g (0.2 mol) N-guanylyield 93.7 percent of theory.
( 2,4-dichloroanilino)-guanidine The hydrochloride melted with decomposition, after recrystallization from tetrahydrofuran/isopropanol, at 235-237C; yield 61 percent of theory. (2,3-dichloroanilino)-guanidine The hydrochloride melted with decomposition, after recrystallization from tetrahydrofuran, at 25 3-254C; yield: 76.6 percent of theory. (4-fluoroanilino)-guanidine The hydrochloride melted with decomposition, after recrystallization from isopropanol/ether, at 2l5-216 C; yield 77.5 percent of theory.
EXAMPLE 2 (3-chloroanilino)-guanidine 7.1 g m-chlorophenyl-hydrazine (0.05 mol) were first heated, while passing nitrogen through the mixture, with 7.7 g S-methyl-isothiuronium bromide for 30 minutes at C and then for 30 minutes at C.
' Thereafter, the base was freed by adding an aqueous chloroanilino)-guanidine hydrochloride having a melting point of l98l99C. The yield amounted to 5 g (45 percent of theory).
The following compounds were obtained in an analogous manner: (2,5-dichloroanilino)-guanidine The hydrobromide melted, after recrystallization from ethyl acetate/methanol, at 202203C; yield: 51 percent of theory. (The crude hydrobromide was recrystallized directly from the melt obtained.) (2,4,6-trichloroanilino)-guanidine The hydrobromide melted, after recrystallization from methanol/ether, at 246-247C; yield: 53 percent of theory. (The crude hydrobromide was recrystallized directly from the melt obtained.) (2,6-dichloroanilino)-guanidine The hydrobromide melted, after recrystallization from alcohol/ether, at 226227C; yield: 61 percent of theory. (The crude hydrobromide was recrystallized directly from the melt obtained.)
EXAMPLE 3 v 2-(2,4-dibromophenyl-hydrazino)-A -imidazoline 6.65 g (0.025 mol) 2,4-dibromophenyl-hydrazine were melted together with 4.95 g (0.025 mol) S- methyl-ethylene-thiourea hydrobromide in a vacuum (12 mm Hg) at l30l40C. After 2 hours had elapsed, the cooled melt was recrystallized from isopropanol. There were obtained 8 g (77.7 percent of theory) 2-( 2 4-dibromophenyl-hydrazino)- -imidazoline hydrobro mide, which had a melting point of 240C.
The following compounds were obtained in an analogous manner: 2-(2,5-dichlorophenyl-hydrazino)-A -imidazoline The hydrobromide melted, after recrystallization from alcohol, at 262263C; yield: 53.3 percent of theory. 2-( 2,6-dichlorophenyl -hydrazino)-A -imidazoline The hydrobromide melted, after recrystallization from alcohol/ether, at 293-294C; yield: 61.3 percent of theory. 2-(2,4-dichlorophenyl-hydrazino)-A -imidazoline The hydrobromide melted, after recrystallization from isopropanol, at 230C; yield: 69.3 percent of theory.
2-( 3 ,4-dichlorophenyl-hydrazino)-A -imidazoline The hydrobromide melted, after recrystallization from isopropanol, at 217C; yield: 53 percent of theory. 2-(2,3-dichlorophenyl-hydrazino)-A -imidazoline The hydrobromide melted, after recrystallization from isopropanol, at 237C; yield: 59 percent of theory. 2-(2,4,6-tribromophenyl-hydrazino)-A -imidazoline The hydrobromide melted, after recrystallization from isopropanol, at 246247C; yield: 46 percent of theory.
2-(4-fluorophenyl-hydrazino)-A -imidazoline The hydrobromide melted, after recrystallization from isopropanol, at l83l85C; yield: 78 percent of theory.
The following compounds were also obtained in an analogous manner but in this instance the reaction was carried out while passing through nitrogen: 2-(3-chlorophenyl-hydrazino)-A -imidazoline The hydrochloride melted, after amorphous reprecipitation, from alcohol/ether, at l67-l70C; yield: 53 percent of theory. 2-(2,4,6-trichlorophenyl-hydrazino)-A -imidazoline The hydrochloride melted, after recrystallization from alcohol, at 262-263C; yield: 52 percent of theory.
The compounds of the invention constitute potent antihypertensive agents. The compounds have proved particularly effective in the treatment of patients with severe or sustained elevation of blood pressure, particularly diastolic pressure. The compounds are suitable for use in almost all forms of fixed and progressive hypertensive disease, including that in which blood pressure is moderately elevated. The compounds have also proved efiective in renal hypertension, including hypertension secondary to pyelonephritis, glomerulonephritis and renal amylordosis.
The compounds can be administered orally, as pills, tablets, capsules, powders and the like. The preferred form of oral administration is as a tablet containing 10 to 25 mg of active compound.
The compounds can also be administered parenterally. injection solutions containing 10 mg/ml of injection solution are preferred.
The dosage schedule is entirely dependent on the condition of the patient, his response to the treatment and whether or not he is ambulatory or hospitalized. The treatment should be begun with small doses (10 mg) and increased gradually depending upon the patients response. The dosage can be increased at 5 to 7 day intervals until an average daily dose of 25 to 50 mg is reached. Only one dose a day is usually required.
In order to establish the effectiveness of the aminoguanidine compounds of the invention as agents for reducing blood pressure a series of tests as follows were carried out.
Rats, each weighing 250-300 g were used as test animals. Experimental hypertension was induced in these animals by administering to them over a 4 week period ll-desoxycorticosterone-acetate (5 mg-twice weekly subcutaneously and by supplying them with a feed containing 10 percent sodium chloride. After this period, during which experimental high blood pressure had been achieved, an arterial tonometer catheter was surgically implanted into the carotid artery of each of the animals. Blood pressure measurements were carried out using an electromechanical pressure converter (Statham element) and a direct writing system (Schwarzer system) for recording the same. After the control values had been determined, the animals were given the test substance dissolved in physiological saline, the test drugs being supplied by an esophageal catheter. l, 2 and 3 hours after administration of the test drug, the animals blood pressure was again determined. All of the values as reported in the table which follows represent average values for arterial pressure. The average values determined at the beginning of the experiment, i.e., prior to drug administration amounted to -180 mm Hg. Groups of 10 animals were used in connection with each drug, therefore the average values are averages determined for 10 animals.
As comparison compound, guanethidine (Ismelin Ciba) [2-(octahydro-l-azocinyl)-ethyl]-guanidine sulfate was used.
The following compounds were used in the tests:
A- [2-( octahydrol -azocinyl )-ethyl ]-guanidinesulfate B- 2-(2,4,6-trichlorophenylhydrazino)- imidazoline-N-hydrochloride C 2(3-chlorophenylhydrazino)-imidazoline-A hydrochloride TABLE Blood Pressure Decrease Maximal Decrease in Average Dose in Arterial Blood Pressure mg./kg. in mm. Hg
Compound Oral G 50 21 H 50 38 l 50 33 J 50 46 K 50 44 As can be seen from the above table, 50 mg/kg of the comparison compound guanethidine resulted in a decrease in average arterial blood pressure of 26 mm Hg, while in all but two instances, the compounds of the invention produced a substantially more marked decrease. In the two instances where the decrease did not exceed that of the control preparation, the values were not significantly different.
It is to be noted in this connection that the use of guanethidine can lead to disturbing and serious clinical problems in particular adverse reactions resulting from sympathetic blockage. These side effects are not observed in connection with the claimed compounds.
We claim:
1. (2,5-dichloroanilino)-guanidine.
2. (2,4,6-trichloroanilino)-guanidine.
3. (2,4-dichloroanilino)-guanidine.
4. (2,6-dichloroanilino)-guanidine.
5. (4,fluoroanilino)-guanidine.
I Inventor(s) Boehr. 329
I UNITED sir/mes PA'IENT 0mm: 9 CER'IIFICATE OF CORREQTKGN name; No. 3, 83,023
Warner Winter et a1 It is certified that error appears in the above-identified patent I 01; l head, I
v and thatsaid Letters Patent are hereby corrected as shown below:
after inventor listing, please insert the name of the assignee; viz Boehringer Mannheim GMBH, of Mannheim,
EDWARD M.'FLETGHER,JR. Attes ting Officer Germany.
Col. 2 line 3.4,
For 9 -"chloroanilino-" Read g-chlo'roanilino cdilughqu l ine. 32,..- I For I I -imt'tdazoline" Read A -imidazo1ine Signed and sealed this 20th day of February 1973.
- (SEAL? Attest':
ROBERT GOTTSCHALK Commissioner of Patents
Claims (4)
- 2. (2,4,6-trichloroanilino)-guanidine.
- 3. (2,4-dichloroanilino)-guanidine.
- 4. (2,6-dichloroanilino)-guanidine.
- 5. (4,fluoroanilino)-guanidine.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1768867A DE1768867C3 (en) | 1968-07-09 | 1968-07-09 | Aminoguanidine derivatives, processes for their production and their use for the production of medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
US3683023A true US3683023A (en) | 1972-08-08 |
Family
ID=5699892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US828366A Expired - Lifetime US3683023A (en) | 1968-07-09 | 1969-05-27 | Amino-guanidine derivatives |
Country Status (9)
Country | Link |
---|---|
US (1) | US3683023A (en) |
AT (1) | AT292010B (en) |
CA (1) | CA954142A (en) |
CH (1) | CH511817A (en) |
DE (1) | DE1768867C3 (en) |
FI (1) | FI50114C (en) |
FR (1) | FR2012562A1 (en) |
GB (1) | GB1217805A (en) |
NL (1) | NL6910469A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4184492A (en) * | 1975-08-07 | 1980-01-22 | Karl Storz Endoscopy-America, Inc. | Safety circuitry for high frequency cutting and coagulating devices |
US4209624A (en) * | 1976-10-26 | 1980-06-24 | Cooper Laboratories, Inc. | Process for preparing substituted bis(amidinoureas) |
US6136987A (en) * | 1998-10-29 | 2000-10-24 | Rhein Chemie Rheinau Gmbh | Use of arylguanidinium xanthogenates as vulcanization accelerators and process for the production thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU190639B (en) * | 1983-12-12 | 1986-09-29 | Gyogyszerkutato Intezet Kv,Hu | Process for production of new aminoguanidin derivatives |
EP0325936A3 (en) * | 1988-01-16 | 1990-01-17 | Ono Pharmaceutical Co., Ltd. | Aminoguanidine derivatives and inhibitory agents on maillard reaction containing them as active ingredients |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3383409A (en) * | 1966-11-10 | 1968-05-14 | Wander Ag Dr A | Beta-(2, 6-dihalophenyl) ethylamino guanidines and the salts thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE558299A (en) * |
-
1968
- 1968-07-09 DE DE1768867A patent/DE1768867C3/en not_active Expired
-
1969
- 1969-05-27 US US828366A patent/US3683023A/en not_active Expired - Lifetime
- 1969-07-03 CA CA056,092A patent/CA954142A/en not_active Expired
- 1969-07-07 CH CH1034069A patent/CH511817A/en not_active IP Right Cessation
- 1969-07-07 GB GB34186/69A patent/GB1217805A/en not_active Expired
- 1969-07-07 FI FI692008A patent/FI50114C/en active
- 1969-07-08 NL NL6910469A patent/NL6910469A/xx unknown
- 1969-07-08 AT AT655569A patent/AT292010B/en not_active IP Right Cessation
- 1969-07-08 FR FR6923147A patent/FR2012562A1/fr not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3383409A (en) * | 1966-11-10 | 1968-05-14 | Wander Ag Dr A | Beta-(2, 6-dihalophenyl) ethylamino guanidines and the salts thereof |
Non-Patent Citations (1)
Title |
---|
Chemical Abstracts, Vol. 67, 32382(a) (1967). * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4184492A (en) * | 1975-08-07 | 1980-01-22 | Karl Storz Endoscopy-America, Inc. | Safety circuitry for high frequency cutting and coagulating devices |
US4209624A (en) * | 1976-10-26 | 1980-06-24 | Cooper Laboratories, Inc. | Process for preparing substituted bis(amidinoureas) |
US6136987A (en) * | 1998-10-29 | 2000-10-24 | Rhein Chemie Rheinau Gmbh | Use of arylguanidinium xanthogenates as vulcanization accelerators and process for the production thereof |
MY119688A (en) * | 1998-10-29 | 2005-06-30 | Rhein Chemie Rheinau Gmbh | Use of arylguanidinium xanthogenates as vulcanization accelerators and process for the production thereof |
Also Published As
Publication number | Publication date |
---|---|
FI50114B (en) | 1975-09-01 |
GB1217805A (en) | 1970-12-31 |
NL6910469A (en) | 1970-01-13 |
AT292010B (en) | 1971-08-10 |
DE1768867C3 (en) | 1973-12-20 |
DE1768867B2 (en) | 1973-05-24 |
FR2012562A1 (en) | 1970-03-20 |
DE1768867A1 (en) | 1972-01-13 |
FI50114C (en) | 1975-12-10 |
CH511817A (en) | 1971-08-31 |
CA954142A (en) | 1974-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU1349700A3 (en) | Method of obtaining (2-oxo-1,2,3,5-tetrahydroimidazo-/2,1b/ quinazolynyl) oxyalkylamides,their optical isomers or pharmaceutically acceptable salts with acids | |
US3803324A (en) | Amino-guanidine derivatives useful for regulating blood pressure | |
US3673241A (en) | Substituted benzaldehyde guanylhydrazones | |
US3632645A (en) | Substituted phenylacetyl derivatives of guanidine o-alkylisoureas s-alkylisothioureas and p-nitrobenzylisothiourea | |
HU208811B (en) | Process for producton of biaryl-compounds and pharmaceutical compositions comprising them as medical agent | |
GB1601195A (en) | 4-acylamino-or 4-acylaminoalkyl-benzoic acids derivatives thereof and processes for their manufacture | |
US3683023A (en) | Amino-guanidine derivatives | |
JPS60178855A (en) | Novel aminoguanidine derivative and manufacture | |
US4163058A (en) | Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof | |
US4087526A (en) | (3-Amino-5-substituted-6-fluoropyrazinoyl or pyrazamido)-guanidines and their derivatives bearing substituents on the guanidino nitrogens | |
EA008249B1 (en) | Novel prodrug of 1-methyl-2(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(n-2-pyridil-n-2-hydroxycarbonylethyl)-amide, production and use thereof as medicaments | |
US4985453A (en) | Parabanic acid derivatives and pharmaceutical compositions thereof | |
US3470297A (en) | Coronary dilating compositions and their administration | |
US3822262A (en) | Phenyl acetylimino-imidazolines and-hexahydropyrimidines | |
US3632602A (en) | 2-(2-arylhydrazino)-2-imidazolines | |
EP0026989B1 (en) | Nitrosourea derivatives, process for preparing them, and pharmaceutical compositions containing them | |
US4367239A (en) | Nitrosourea derivatives, pharmaceutical compositions thereof and method of preparation | |
US3928590A (en) | Ortho-mercaptoaroylamides and salts thereof as hypoglycemic agents | |
US3840539A (en) | Phthalazine derivatives | |
US2928768A (en) | Use of substituted amino-formoguanamines in diuretic therapy | |
US4322434A (en) | N-Substituted-4-(polyfluoro-2-hydroxy-2-propyl)anilines and compounds related thereto | |
GB2093450A (en) | 2,1,3-benzothiadiazole derivatives | |
US4713390A (en) | Sulfurated hydantoin derivatives and pharmaceutical compositions containing same | |
US4229462A (en) | Method for controlling hypertension and compositions | |
US3829488A (en) | Bis-(o-n-substituted-carbamylphenyl)disulfide and mercapto reduction product |